The Mitochondrial Myopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mitochondrial Myopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mitochondrial Myopathy and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Mitochondrial Myopathy by eight companies/universities/institutes. The top development phase for Mitochondrial Myopathy is preclinical with two drugs in that stage. The Mitochondrial Myopathy pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Mitochondrial Myopathy pipeline products market are: Abliva, OMEICOS Therapeutics and Stealth BioTherapeutics.
The key targets in the Mitochondrial Myopathy pipeline products market include Thymidine Phosphorylase, NAD(P)H Dehydrogenase [Quinone] 1, and Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial.
The key mechanisms of action in the Mitochondrial Myopathy pipeline product include Polyunsaturated Fatty Acid Lipoxygenase ALOX15 Inhibitor with one drug in Phase III. The Mitochondrial Myopathy pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Mitochondrial Myopathy pipeline products market including Small Molecule, and Gene Therapy.
Mitochondrial Myopathy overview
Mitochondria are known as “the powerhouse of the cell,” but when defects occur they give rise to mitochondrial diseases. Mitochondrial diseases affecting the muscles are known as mitochondrial myopathies. These can occur because of fetal gene mutations in the mitochondria, resulting in childhood myopathies. Symptoms include fatigue, muscle weakness, stunted growth, and exercise intolerance, as production of adenosine triphosphate (ATP), a cellular fuel, is reduced. This can lead to cardiac, respiratory, and neurological complications, among others. Diagnosis is done based on the history of familial hereditary diseases, followed by physical and laboratory examinations like muscle biopsy, imaging to eliminate other neurological and cardiac diseases, and metabolic complications. Management of this condition is mainly symptomatic and to prevent complications. Physical exercise is prescribed to improve muscle condition and dexterity, and nutrient supplements can play a role.
For a complete picture of Mitochondrial Myopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
